加维斯替奈 T22798

Product Introduction
Bioactivity


英文名: Gavestinel

描述: Gavestinel (GV 150526) 是一种非竞争性的 NMDA 受体拮抗剂，具有有效性、选择性和口服活性。Gavestinel 可与 NMDA 受体的甘氨酸位点结合，其结合亲和力(pKi 值)为 8.5。Gavestinel 可用于急性缺血性脑卒中研究。

体内活性: Gavestinel (800 mg) was administered as a loading dose and followed by either 100 mg, 200 mg, or 400 mg maintenance doses given every 12 h for five doses. The mean terminal half-life ranged from 29 h to 56 h. Gavestinel was extensively bound to plasma protein (median percentage free <0.01). During gavestinel administration, some patients exhibited elevated levels of bilirubin, which may be the result of shared mechanisms of elimination (glucuronide conjugation and excretion in bile).[2]

存储条件: Powder: -20°C for 3 years | In solvent: -80°C for 1 year

溶解度: DMSO : 90.0 mg/mL (226.6 mM)


关键字: Gavestinel sodium | Gavestinel | GV-150526 | GV150526

相关产品: Orphenadrine hydrochloride | Dizocilpine Maleate | Perzinfotel | SDZ 220-040 | Caroverine hydrochloride | DL-AP5 | Transcrocetinate disodium | L-Cysteine S-sulfate | Radiprodil | NKH477

相关库: Anti-Neurodegenerative Disease Compound Library | Membrane Protein-targeted Compound Library | Bioactive Compounds Library Max | Neuronal Signaling Compound Library | Bioactive Compound Library

加维斯替奈 T22798信息由TargetMol中国为您提供，如您想了解更多关于加维斯替奈 T22798报价、型号、参数等信息，欢迎来电或留言咨询。

注：该产品未在中华人民共和国食品药品监督管理部门申请医疗器械注册和备案，不可用于临床诊断或治疗等相关用途